Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Chae Yoon Chon"

Article category

Keywords

Publication year

"Chae Yoon Chon"

Original Article

Viral hepatitis

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
Mi Sung Park, Beom Kyung Kim, Kyung Sik Kim, Ja Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Oidov Baartarkhuu, Kwang Hyub Han, Chae Yoon Chon, Sang Hoon Ahn
Korean J Hepatol 2013;19(1):29-35.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.29
Background/Aims

The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment.

Methods

Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks.

Results

The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log10 IU/mL, week 96: -4.27 log10 IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P=0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm.

Conclusions

There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.

Citations

Citations to this article as recorded by  Crossref logo
  • ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis
    Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2023; 21(9): 2278.     CrossRef
  • Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
    David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Entecavir-based combination therapies for chronic hepatitis B
    Aoran Luo, Xiaoyan Jiang, Hong Ren
    Medicine.2018; 97(51): e13596.     CrossRef
  • Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China
    Keng Lai, Chi Zhang, Weixia Ke, Yanhui Gao, Shudong Zhou, Li Liu, Yi Yang
    Clinical Drug Investigation.2017; 37(3): 233.     CrossRef
  • De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
    Song Yang, Huichun Xing, Qi Wang, Xiaomei Wang, Shunai Liu, Jun Cheng
    Annals of Clinical Microbiology and Antimicrobials.2016;[Epub]     CrossRef
  • The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
    Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon
    Clinical and Molecular Hepatology.2016; 22(2): 241.     CrossRef
  • Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B
    YANG WANG, SHUANG LIU, YU CHEN, SUJUN ZHENG, LI ZHOU, FENGMIN LU, ZHONGPING DUAN
    Experimental and Therapeutic Medicine.2016; 11(6): 2293.     CrossRef
  • Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
    Sung Soo Ahn, Young Eun Chon, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
    Clinical and Molecular Hepatology.2014; 20(3): 261.     CrossRef
  • Oral antiviral agents for treatment of chronic hepatitis B
    Soon Young Ko, Won Hyeok Choe
    Journal of the Korean Medical Association.2014; 57(1): 60.     CrossRef
  • Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment
    A. K. Singh, M. K. Sharma, S. S. Hissar, E. Gupta, S. K. Sarin
    Journal of Viral Hepatitis.2014; 21(6): 439.     CrossRef
  • Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
    Hyung Joon Yim, Seong Gyu Hwang
    Clinical and Molecular Hepatology.2013; 19(3): 195.     CrossRef
  • 10,339 View
  • 63 Download
  • Crossref
Case Report
Hepatogastric fistula caused by direct invasion of hepatocellular carcinoma after transarterial chemoembolization and radiotherapy
Hana Park, Seung Up Kim, Junjeong Choi, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, Chae Yoon Chon, Young Nyun Park, Do Young Kim
Korean J Hepatol 2010;16(4):401-404.
Published online December 31, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.4.401

A 63-year-old man with a history of hepatitis-B-related hepatocellular carcinoma (HCC) in the left lateral portion of the liver received repeated transcatheter arterial chemoembolization (TACE) and salvage radiotherapy. Two months after completing radiotherapy, he presented with dysphagia, epigastric pain, and a protruding abdominal mass. Computed tomography showed that the bulging mass was directly invading the adjacent stomach. Endoscopy revealed a fistula from the HCC invading the stomach. Although the size of the mass had decreased with the drainage through the fistula, and his symptoms had gradually improved, he died of cancer-related bleeding and hepatic failure. This represents a case in which an HCC invaded the stomach and caused a hepatogastric fistula after repeated TACE and salvage radiotherapy.

Citations

Citations to this article as recorded by  Crossref logo
  • Unusual upper gastrointestinal bleeding following radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma
    CW Chang, HW Wang, WH Huang, PH Chuang
    Journal of Postgraduate Medicine.2023; 69(4): 237.     CrossRef
  • Hepatic artery pseudo-aneurysm rupturing into hepato-gastric fistula, a rare cause of massive upper gastrointestinal hemorrhage: Case report
    Arkadeep Dhali, Avik Sarkar, Sukanta Ray, Dijendra Nath Biswas, Gopal Krishna Dhali, Ankit Mahajan
    Radiology Case Reports.2022; 17(1): 133.     CrossRef
  • Hepatocellular Carcinoma with Gastrointestinal Involvement: A Systematic Review
    Cristiana Marinela Urhut, Larisa Daniela Sandulescu, Liliana Streba, Vlad Florin Iovanescu, Sarmis Marian Sandulescu, Suzana Danoiu
    Diagnostics.2022; 12(5): 1270.     CrossRef
  • Malignant hepatogastric fistula with associated secondary liver abscess: a rare complication of an occult gastric adenocarcinoma
    Alexander Mimery, Nicolas Ramly, Amitabha Das, Kheman Rajkomar
    BMJ Case Reports.2021; 14(8): e240238.     CrossRef
  • Upper Gastrointestinal Bleed Due to Invasive Hepatocellular Carcinoma and Hepato-Gastric Fistula
    Abhijith Bale, Shiran Shetty, Anurag Shetty, Girisha Balaraju, Cannanore Ganesh Pai
    Journal of Clinical and Experimental Hepatology.2018; 8(1): 104.     CrossRef
  • Gastric Metastasis of Hepatocellular Carcinoma With Gastrointestinal Bleeding After Liver Transplant: A Case Report
    L. Li, W.H. Zhang, F.P. Meng, X.M. Ma, L.J. Shen, B. Jin, H.W. Li, J. Han, G.D. Zhou, S.H. Liu
    Transplantation Proceedings.2015; 47(8): 2544.     CrossRef
  • Hepatoduodenal fistula formation following transcatheter arterial chemoembolization and radiotherapy for hepatocellular carcinoma: treatment with endoscopic Histoacryl injection
    Jaryong Jeon, Joonseong Ahn, Hongseok Yoo, Taek Kyu Park, Dongmo Je, Hyemin Jeong, Kwang Hyuck Lee
    The Korean Journal of Internal Medicine.2014; 29(1): 101.     CrossRef
  • Hepatogastric fistula: a rare complication of pyogenic liver abscess
    Venkata Srinivas Gandham, Biju Pottakkat, Lakshmi C Panicker, Ranjit Vijaya Hari
    BMJ Case Reports.2014; 2014: bcr2014204175.     CrossRef
  • 9,567 View
  • 64 Download
  • Crossref